Abstract
Lipid modification following stroke is a key intervention to reduce the risk of recurrent stroke. The evidence supports the use of statins towards this aim, with the suggestion that intensive lipid lowering is preferable. Maintaining compliance with statin therapy is a significant challenge for long-term management. There is no direct evidence to support the efficacy of nonstatin agents as monotherapy or add-on therapy in reducing clinical outcomes in this population of people with cerebrovascular disease and further research is required.